Physician profile
Robert J Stoffa
NPI 1871586644
$5,766.81
in general payments reported to CMS, 2019-2025
51 companies · $692 in 2025
The $692 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,300 · 2020: $179 · 2021: $125 · 2022: $507 · 2023: $704 · 2024: $1,259 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,630 · Education: $25.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,630.21 |
| Education | $25.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,012.22 | 2019-2025 | Linzess, Viberzi, Humira |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $577.04 | 2019-2024 | Trulance, Xifaxan, Plenvu |
| Phathom Pharmaceuticals, INC. | $563.86 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $527.54 | 2019-2025 | Entyvio, Eohilia |
| Regeneron Healthcare Solutions, INC. | $392.77 | 2022-2025 | Dupixent |
| Genzyme Corporation | $337.55 | 2019-2024 | |
| Braintree Laboratories, INC. | $193.31 | 2019-2025 | Suflave, Sutab |
| Ironwood Pharmaceuticals, INC | $161.74 | 2019-2024 | Linzess |
| Janssen Biotech, INC. | $135.45 | 2019-2025 | Tremfya |
| Dova Pharmaceuticals | $134.86 | 2019 | |
| Janssen Scientific Affairs, LLC | $125.00 | 2019 | |
| Ucb, INC. | $122.47 | 2019 | |
| Novo Nordisk INC | $95.00 | 2019-2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $88.28 | 2019 | |
| Celgene Corporation | $77.00 | 2023-2024 | Zeposia |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Stoffa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.